2022
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnelLong-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroupYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2020
A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention
Nally LM, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M. A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. Endocrine Practice 2020, 27: 545-551. PMID: 34120699, PMCID: PMC8206518, DOI: 10.1016/j.eprac.2020.11.017.Peer-Reviewed Original ResearchAlcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking statusTime spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study
DiMeglio LA, Kanapka LG, DeSalvo DJ, Anderson BJ, Harrington KR, Hilliard ME, Laffel LM, Tamborlane WV, Van Name MA, Wadwa RP, Willi SM, Woerner S, Wong JC, Miller KM, Group F. Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabetic Medicine 2020, 37: 1308-1315. PMID: 32096282, PMCID: PMC9065795, DOI: 10.1111/dme.14276.Peer-Reviewed Original ResearchChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidenceGreater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring
Van Name MA, Miller KM, Commissariat PV, Whitehouse AL, Harrington KR, Anderson BJ, Mantravadi MG, Levy W, DeSalvo DJ, Tamborlane WV, Hilliard ME, Laffel LM, DiMeglio LA. Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabetic Medicine 2019, 36: 1508-1510. PMID: 31295359, PMCID: PMC7027357, DOI: 10.1111/dme.14074.Peer-Reviewed Original ResearchBenefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes
Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA. Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 493-498. PMID: 31287721, PMCID: PMC6708264, DOI: 10.1089/dia.2019.0142.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringCGM useDiabetes managementDiabetes careBenefits of CGMYoung childrenGlucose monitoringMean child ageChildren's diabetes careType 1 diabetes managementPainful insertionT1D durationParents of childrenGlucose excursionsImproved sleepClinical strategiesSemistructured qualitative interviewsType 1Parental comfortChild's ageChildrenBehavioural supportMultiple barriersParents' experiencesCaregiversPharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsImpact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrateInsulin Pump Use in Young Children with Type 1 Diabetes: Sociodemographic Factors and Parent-Reported Barriers
Commissariat PV, Boyle CT, Miller KM, Mantravadi MG, DeSalvo DJ, Tamborlane WV, Van Name MA, Anderson BJ, DiMeglio LA, Laffel LM. Insulin Pump Use in Young Children with Type 1 Diabetes: Sociodemographic Factors and Parent-Reported Barriers. Diabetes Technology & Therapeutics 2017, 19: 363-369. PMID: 28581817, PMCID: PMC6435342, DOI: 10.1089/dia.2016.0375.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolCohort StudiesCross-Sectional StudiesDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHealth Care SurveysHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsMaleMonitoring, AmbulatoryParentsPatient Acceptance of Health CarePatient PreferenceRegistriesSocioeconomic FactorsUnited StatesConceptsBlood glucose monitoringContinuous glucose monitoringGlycemic controlGlucose monitoringMore frequent blood glucose monitoringPump usersYoung childrenFrequent blood glucose monitoringParent-reported reasonsDuration of diabetesOverall glycemic controlInsulin pump useT1D Exchange RegistryParent-reported barriersType 1 diabetesAnnual household incomeClinical characteristicsT1D durationParents of childrenPump therapyCGM usePump useSociodemographic factorsTherapeutic effectivenessType 1Nighttime is the worst time: Parental fear of hypoglycemia in young children with type 1 diabetes
Van Name MA, Hilliard ME, Boyle CT, Miller KM, DeSalvo DJ, Anderson BJ, Laffel LM, Woerner SE, DiMeglio LA, Tamborlane WV. Nighttime is the worst time: Parental fear of hypoglycemia in young children with type 1 diabetes. Pediatric Diabetes 2017, 19: 114-120. PMID: 28429581, PMCID: PMC5650950, DOI: 10.1111/pedi.12525.Peer-Reviewed Original ResearchSchooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings
Erie C, Van Name MA, Weyman K, Weinzimer SA, Finnegan J, Sikes K, Tamborlane WV, Sherr JL. Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings. Pediatric Diabetes 2017, 19: 92-97. PMID: 28303678, PMCID: PMC5601025, DOI: 10.1111/pedi.12518.Peer-Reviewed Original Research
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriod